Key Takeaways
Sarepta Therapeutics Inc. (SRPT) saw its shares fall 5.3% in after-hours trading despite reporting first-quarter revenue of $730.8 million that significantly outpaced Wall Street estimates.
“Our commercial portfolio has begun to stabilize, supported by expanded field engagement and a growing body of evidence reinforcing the disease‑modifying impact of ELEVIDYS, which we believe is positioned to return to growth,” said Doug Ingram, chief executive officer of Sarepta Therapeutics.
The company’s results comfortably exceeded analyst projections, with adjusted earnings of $3.16 per share surpassing the 90-cent consensus estimate. However, the headline beat was overshadowed by a steep decline in product sales, which fell 46% from the prior year to $330.5 million. The drop was attributed to lower demand for its flagship Duchenne muscular dystrophy gene therapy, Elevidys. Collaboration revenue, primarily from an agreement with Roche Holding AG, bolstered the top line with $400.3 million.
The focus for investors remains on Elevidys, which has faced significant challenges. Following safety events in 2025, the therapy’s label was updated to restrict its use to ambulatory patients aged 4 and older. More critically, it now carries a boxed warning—the FDA’s most severe safety notice—for the risk of fatal liver injury. This has sharply reduced the drug's addressable market and shaken investor confidence, with the company's stock down nearly 37% over the past year.
Despite the challenges, Sarepta reiterated its full-year 2026 guidance for total product revenues between $1.2 billion and $1.4 billion. The company is also advancing other treatments, including its siRNA pipeline, which recently delivered encouraging early data.
The negative stock reaction shows that investors are more concerned with the future of Sarepta's core commercial product than with a top-line beat driven by collaboration revenue. The company's ability to rebuild trust in Elevidys and demonstrate a return to growth will be the key catalyst for the stock going forward.
This article is for informational purposes only and does not constitute investment advice.
